Cell and Gene Therapy
A section of Cells (ISSN 2073-4409).
Section Information
Cell- and gene-based therapies are transforming human translational medicine. They have redefined our understanding of fundamental cell biology while driving the development of clinically viable interventions for complex and age-related diseases. As these fields mature, engineering the next generation of therapeutics demands greater precision, efficacy, and personalization. This requires overcoming several critical scientific and translational challenges, including:
- Enhancing the physiological and anatomical fidelity of engineered human tissues.
- Maximizing target specificity through precision genetic engineering technologies.
- Resolving barriers to immunity, safety, and durable performance.
- Establishing scalable, cost-effective, and clinically compliant manufacturing processes.
- Developing real time and non-invasive tracking to assess therapeutic responses.
Addressing these multi-dimensional challenges necessitates robust, cross-disciplinary collaboration. The Cell and Gene Therapy Section serves as an ideal forum for the dissemination of high-impact research addressing these critical bottlenecks. This includes pioneering methodologies in emerging domains, such as New Approach Methodologies, to reduce the use of animal models in preclinical research.
We welcome original research, review articles, and communications, on topics including, but not limited to, the following:
1. Advanced Therapeutics and Translational Medicine
- Adoptive Cell and CAR-T/TCR-T Therapies;
- Immunotherapy and Vaccinology;
- Stem Cell Biology and Regenerative Medicine;
- RNA and Genomic Medicine.
2. Genetic Modalities and Delivery Vectors
- Advanced Genome Editing;
- Viral and Non-Viral Vector Engineering;
- Oncolytic Virology;
- Epigenetic Regulation,
3. Tissue Engineering
- Biomaterials;
- Tissue Regeneration and Repair;
- Synthetic Biology;
- Preclinical Modelling,
4. Manufacture, Safety, and Tracking
- Administration and Targeting;
- Transplantation;
- Therapeutic Stability;
- Immune Compatibility;
- Non-Invasive and Real Time Monitoring.
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Epigenetic Plasticity: How Chromatin Dynamics Orchestrate Fundamental Life Processes (Deadline: 30 August 2026)
- New Trends and Advances in Molecular Targeted Therapy for Cancers (Deadline: 31 August 2026)
- Gene and Cell Therapy in Regenerative Medicine—Third Edition (Deadline: 31 August 2026)
- The Silent Regulators: Non-Coding RNAs in Cell Function and Disease (Deadline: 25 September 2026)
- mRNA Regulation in Endoplasmic Reticulum Stress and Protein Homeostasis (Deadline: 30 September 2026)
- Interactions Between Gut Microbiota and Epigenetic Markers in Health and Disease (Deadline: 31 October 2026)
- MicroRNAs in Atherosclerosis: Mechanisms, Biomarkers, and Therapeutic Opportunities (Deadline: 31 October 2026)
- Molecular Genetics of Cystic Kidney Disease (Deadline: 31 October 2026)
- Epigenetic Regulation of Cellular Plasticity in Brain Tumors (Deadline: 31 October 2026)
- Mechanisms of Transcriptional Regulation in Disease: From Chromatin Dynamics to Therapeutic Innovation (Deadline: 30 November 2026)
- Genome Editing in Biomedicine (Deadline: 30 November 2026)
- Interaction Between DNA Damage Response and Anti-Cancer Immunity (Deadline: 30 November 2026)
- Gene Regulation in Epithelial Cells (Deadline: 29 January 2027)
- The Power of Small Molecules in Cancer (Deadline: 10 February 2027)
